Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Metabolon Strengthens Metabolomics Leadership with Acquisition of Lipomics Technologies

Published: Friday, August 03, 2012
Last Updated: Friday, August 03, 2012
Bookmark and Share
Gains proprietary lipids technology platform and further opportunities for diagnostics, personalized medicine and commercial services.

Metabolon, Inc. has announced the completion of its acquisition of Lipomics Technologies, Inc. This transaction combines Metabolon’s world-leading metabolomics technology platform for commercial services and diagnostics with Lipomics’ world-leading TrueMass® Profiling lipids technology platform.

Lipomics’ laboratory facilities will remain at its headquarters in Sacramento, California while Metabolon’s headquarters and laboratories will remain in Research Triangle Park.

Steven M. Watkins, Ph.D., Lipomics’ founder, will join Metabolon’s executive team as chief technology officer. Financial terms of the transaction were not disclosed.

Michael Milburn, Ph.D., chief scientific officer of Metabolon, stated, “Metabolon has pioneered metabolomics technology and is the largest provider of solutions globally to the pharmaceutical, healthcare, consumer products, nutrition and agricultural industries, as well as to hundreds of academic institutions. Lipomics is the leader in technology to analyze lipids, including metabolites of fatty acids, acylcarnitines, sterols, amino acids, bile acids and eicosanoids. Together we have an unprecedented suite of technologies and capabilities to benefit our expanding customer base. The combined technologies will deliver new and improved diagnostic products and personalized medicine solutions for unmet needs, particularly in metabolic disease and cancer.”

“For the past 10 years Lipomics has taken pride in providing the best technology and science for understanding the role of lipids in human disease, principally in metabolic diseases associated with obesity and the lipid remodeling aspects of cancer,” said Dr. Watkins.

Dr. Watkins continued, “The prospect of combining our approach with Metabolon’s global platform is extremely exciting. Integrating the technologies will provide a deep and coherent understanding of biological systems and allow us to produce unparalleled services and products for years to come.”

John Ryals, Ph.D., chief executive officer of Metabolon, expressed his support of the acquisition saying, “By combining Metabolon and Lipomics, we have created the undisputed technology leader in the emerging field of metabolomics. We have product offerings that span from global metabolomics to complex lipid analysis to targeted analysis of many different classes of molecules. By combining our two companies, we have more than 140 employees and 450 clients, have completed 2,000 commercial projects and have 200 scientific papers either published or under review. We are not aware of another company or institution with this record of scientific and commercial achievement in the field of metabolomics.

“We are the leader in the commercialization of metabolomics with a profitable commercial life sciences service business and have launched the world’s first metabolomics-based diagnostic test for type 2 diabetes risk based on biomarkers that measure insulin resistance. We expect that in 2013 we will be marketing additional diagnostic products aimed at diseases related to obesity and cancer, and are committed to maintaining our position as the world’s leader in metabolomics.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Metabolon Launches Strategic Outsourcing Programs Focused On Disease Metabolism
Metabolon’s partners will collaborate toward shared objectives through this program.
Monday, October 15, 2012
Metabolon Files Patent Infringement Lawsuit against Stemina
The lawsuit requests monetary damages as well as an order permanently enjoining Stemina from continued acts of infringement.
Tuesday, August 28, 2012
Metabolon Technology Now Available in Germany
The Helmholtz Zentrum Muenchen, Research Center for Environmental Health in Neuherberg, Germany, has successfully completed Metabolon’s validation requirements.
Friday, July 13, 2012
Metabolon’s Shanghai Jiao Tong University Lab Receives Validation
The joint metabolomics laboratory passed the quality control processes and has officially started operation.
Monday, May 14, 2012
Takeda and Metabolon Initiate Research Collaboration
Multiyear research alliance to discover novel targets and biomarkers.
Wednesday, April 18, 2012
Metabolon Awarded Analytical Methods Patent
The patented method enables the researcher to process, analyze and interpret data more efficiently.
Thursday, March 29, 2012
Metabolon Receives Accreditation by College of American Pathologists
Metabolon, Inc. announces that they have received laboratory accreditation from the College of American Pathologists (CAP).
Tuesday, December 06, 2011
Metabolomics Insight into Periodontal Disease Published in the Journal of Dental Research
Data reveal altered host-bacteria interactions associated with periodontitis.
Monday, October 24, 2011
Metabolon and SJTU Open Metabolomics Lab in China
Shanghai facility is company’s first foray into Asia.
Tuesday, October 18, 2011
Genome Wide Association Study Published in Nature
Metabolon, Inc. announces the publication of “Human Metabolic Individuality in Biomedical and Pharmaceutical Research” in the journal Nature.
Tuesday, September 20, 2011
Metabolon Secures $13 Million in Series D Financing
New investor Keating Capital, Inc. joins existing investors including Sevin Rosen Funds, Aurora Funds, Harris & Harris Group, Syngenta Ventures, Fletcher Spaght and Fulcrum Financial Partners in the round.
Tuesday, August 30, 2011
Two Studies Provide Insight into Kidney Cancer
Metabolon, Inc. announces the publication of studies in two peer-reviewed journals that support the use of metabolomics in the diagnosis and treatment of kidney cancer.
Tuesday, August 16, 2011
Research into Dietary Leucine
Metabolon, Inc. announces the publication of “Dietary Leucine - An Environmental Modifier of Insulin Resistance Acting on Multiple Levels of Metabolism” in PLoS One.
Tuesday, July 19, 2011
USPTO Grants Two New Patents to Metabolon
Metabolon currently holds 17 US Patents related to its biochemical profiling methods, data analysis solutions and biomarkers for disease and toxicity.
Monday, June 20, 2011
Metabolon Awarded Patent in Metabolomics Methods for Drug Discovery
Metabolon, Inc. announces that it was awarded US Patent 7,910,301 “Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics” by the United States Patent and Trademark Office.
Tuesday, May 17, 2011
Scientific News
Could the Food we Eat Affect Our Genes?
Almost all of our genes may be influenced by the food we eat, according to new research.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Cytoskeleton Crew
Findings confirm sugar's role in helping cancers survive by changing cellular architecture.
Microbiome May Hold the Key to Fighting Obesity
In a unique study of free-ranging brown bears, Swedish researchers were able to show that the bears’ dietary variation goes hand-in-hand with dramatic changes in the animal’s gut microbiota.
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Toxicity Testing With Cultured Liver Cells
Microreactor replaces animal testing.
Proteins Seek, Attack, Destroy Tumor Cells in Bloodstream
Using white blood cells to ferry potent cancer-killing proteins through the bloodstream virtually eliminates metastatic prostate cancer in mice, Cornell researchers have confirmed.
Why Do Some Infections Persist?
In preparing for the possibility of an antibiotic onslaught, some bacterial cultures adopt an all-for-one/one-for-all strategy that would make a socialist proud, University of Vermont researchers have found.
Flipping Molecular 'Switch' May Reduce Nicotine's Effects in the Brain
Scientists at The Scripps Research Institute (TSRI) have discovered that a lipid (fat molecule) in brain cells may act as a “switch” to increase or decrease the motivation to consume nicotine.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!